• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

    7/3/24 12:55:10 PM ET
    $AZEK
    $CHTR
    $PCRX
    $SPR
    Plastic Products
    Industrials
    Cable & Other Pay Television Services
    Telecommunications
    Get the next $AZEK alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

    • DA Davidson analyst Kurt Yinger downgraded the rating for AZEK Co (NYSE:AZEK) from Buy to Neutral, while lowering the price target from $57 to $44. AZEK shares gained 0.8% to close at $41.63 on Tuesday. See how other analysts view this stock.
    • Barclays analyst David Strauss downgraded Spirit AeroSystems Holdings, Inc. (NYSE:SPR) from Overweight to Equal-Weight and slashed the price target from $40 to $37. Spirit AeroSystems shares fell 0.3% to trade at $33.88 on Tuesday. See how other analysts view this stock.
    • Citigroup analyst Michael Rollins downgraded the rating for Charter Communications, Inc. (NASDAQ:CHTR) from Neutral to Sell and cut the price target from $280 to $255. Charter Communications shares gained 2.5% to close at $303.50 on Tuesday. See how other analysts view this stock.
    • Barclays analyst Balaji Prasad downgraded Pacira BioSciences, Inc. (NASDAQ:PCRX) from Overweight to Equal-Weight and cut the price target from $38 to $25. Pacira BioSciences shares fell 20.1% to trade at $22.74 on Tuesday. See how other analysts view this stock. See how other analysts view this stock.
    • Citigroup analyst Jason Gursky downgraded the rating for Spirit AeroSystems Holdings, Inc. (NYSE:SPR) from Buy to Neutral, while lowering the price target from $39 to $37.25. Spirit AeroSystems shares fell 0.3% to trade at $33.88 on Tuesday. See how other analysts view this stock.

    Check This Out: How To Earn $500 A Month From AZZ Stock Ahead Of Q1 Earnings Report

    Get the next $AZEK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZEK
    $CHTR
    $PCRX
    $SPR

    CompanyDatePrice TargetRatingAnalyst
    Charter Communications Inc.
    $CHTR
    1/13/2026$180.00Equal Weight → Underweight
    Wells Fargo
    Pacira BioSciences Inc.
    $PCRX
    12/9/2025$27.00Equal Weight
    Barclays
    Pacira BioSciences Inc.
    $PCRX
    11/17/2025Buy
    H.C. Wainwright
    Charter Communications Inc.
    $CHTR
    11/4/2025Outperform → Perform
    Oppenheimer
    Charter Communications Inc.
    $CHTR
    11/3/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Charter Communications Inc.
    $CHTR
    11/3/2025$280.00Outperform → Mkt Perform
    Bernstein
    Charter Communications Inc.
    $CHTR
    10/6/2025$325.00Buy
    Citigroup
    Charter Communications Inc.
    $CHTR
    9/2/2025$223.00Sell
    Goldman
    More analyst ratings

    $AZEK
    $CHTR
    $PCRX
    $SPR
    SEC Filings

    View All

    SEC Form 144 filed by Pacira BioSciences Inc.

    144 - Pacira BioSciences, Inc. (0001396814) (Subject)

    2/2/26 10:55:35 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Charter Communications Inc.

    SCHEDULE 13G/A - CHARTER COMMUNICATIONS, INC. /MO/ (0001091667) (Subject)

    1/30/26 1:29:41 PM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    SEC Form 10-K filed by Charter Communications Inc.

    10-K - CHARTER COMMUNICATIONS, INC. /MO/ (0001091667) (Filer)

    1/30/26 7:01:50 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    $AZEK
    $CHTR
    $PCRX
    $SPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pacira to Report 2025 Financial Results on Thursday February 26, 2026

    BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.

    2/12/26 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SPECTRUM LAUNCHES INVINCIBLE WIFI™, INTEGRATING WIFI 7 WITH 5G AND BATTERY BACKUP FOR CONSTANT CONNECTIVITY

    Key Takeaways: Invincible WiFi is the industry's first WiFi 7 service with 5G cellular and battery backup, seamlessly switching connections in the event of a power outage or network disruption.Available to both residential and business customers, Invincible WiFi keeps devices connected through the unexpected.STAMFORD, Conn., Feb. 12, 2026 /PRNewswire/ -- A storm rolls through and your power goes out, but your devices stay connected to WiFi and life keeps moving: working, learning, streaming and gaming continue because of Spectrum's Invincible WiFi™, the industry's first WiFi 7 service with integrated battery and 5G cellular backup. Announced today, Spectrum's Invincible WiFi sets a new stand

    2/12/26 11:00:00 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

    BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction ("NOPAIN") Act. Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation's leading nonpartisan coalition dedicated to ensuring patient access to non-addictive pain management approaches Data were gathered from a national awareness, trial, and usage (ATU) survey of nearly 750 hospitals, he

    2/12/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZEK
    $CHTR
    $PCRX
    $SPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nair Balan bought $98,716 worth of shares (360 units at $274.21), increasing direct ownership by 4% to 9,622 units (SEC Form 4)

    4 - CHARTER COMMUNICATIONS, INC. /MO/ (0001091667) (Issuer)

    8/4/25 8:35:17 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    President and CEO Winfrey Christopher L bought $1,002,259 worth of shares (3,670 units at $273.10), increasing direct ownership by 6% to 70,243 units (SEC Form 4)

    4 - CHARTER COMMUNICATIONS, INC. /MO/ (0001091667) (Issuer)

    7/31/25 4:15:18 PM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:55 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZEK
    $CHTR
    $PCRX
    $SPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Charter Comm downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Charter Comm from Equal Weight to Underweight and set a new price target of $180.00

    1/13/26 9:05:21 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Barclays initiated coverage on Pacira BioSciences with a new price target

    Barclays initiated coverage of Pacira BioSciences with a rating of Equal Weight and set a new price target of $27.00

    12/9/25 8:52:11 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Pacira BioSciences

    H.C. Wainwright initiated coverage of Pacira BioSciences with a rating of Buy

    11/17/25 9:41:22 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZEK
    $CHTR
    $PCRX
    $SPR
    Leadership Updates

    Live Leadership Updates

    View All

    Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

    -- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members. "Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors," said Laura Brege, independent board chair of Pacira. "We believ

    1/28/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

    -- LG Chem becomes exclusive distributor of EXPAREL --  – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-actin

    1/13/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

    --Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale. "Despite its prevalence, there c

    12/18/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZEK
    $CHTR
    $PCRX
    $SPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President, Finance Riker Lauren covered exercise/tax liability with 2,751 shares and sold $83,240 worth of shares (4,000 units at $20.81), decreasing direct ownership by 11% to 52,313 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:24:09 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Administrative Officer Williams Kristen covered exercise/tax liability with 17,134 shares and sold $269,703 worth of shares (13,137 units at $20.53), decreasing direct ownership by 19% to 131,303 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:24:01 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Teehan Brendan covered exercise/tax liability with 5,182 shares, decreasing direct ownership by 10% to 49,220 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:23:46 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZEK
    $CHTR
    $PCRX
    $SPR
    Financials

    Live finance-specific insights

    View All

    Pacira to Report 2025 Financial Results on Thursday February 26, 2026

    BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.

    2/12/26 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Charter Announces Fourth Quarter and Full Year 2025 Results

    STAMFORD, Conn., Jan. 30, 2026 /PRNewswire/ -- Charter Communications, Inc. (along with its subsidiaries, the "Company" or "Charter"), which operates the Spectrum brand, today reported financial and operating results for the three and twelve months ended December 31, 2025. Fourth quarter total Internet customers declined by 119,000. As of December 31, 2025, Charter served 29.7 million Internet customers.Fourth quarter total mobile lines1 increased by 428,000. As of December 31, 2025, Charter served 11.8 million mobile lines.As of December 31, 2025, customer relationships2 tota

    1/30/26 7:00:00 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

    -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Total revenues of $179.5 millionNet product sales of $139.9 million for EXPAREL; $29.0 million for ZILRETTA; and $6.5 million for iovera°Net income of $5.4 million, or $0.12 per sha

    11/6/25 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZEK
    $CHTR
    $PCRX
    $SPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spirit Aerosystems Holdings Inc.

    SC 13G/A - Spirit AeroSystems Holdings, Inc. (0001364885) (Subject)

    11/14/24 5:12:55 PM ET
    $SPR
    Military/Government/Technical
    Industrials

    SEC Form SC 13G filed by Spirit Aerosystems Holdings Inc.

    SC 13G - Spirit AeroSystems Holdings, Inc. (0001364885) (Subject)

    11/14/24 4:05:10 PM ET
    $SPR
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by Spirit Aerosystems Holdings Inc.

    SC 13G/A - Spirit AeroSystems Holdings, Inc. (0001364885) (Subject)

    11/14/24 1:22:34 PM ET
    $SPR
    Military/Government/Technical
    Industrials